Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioXcel Therapeutics (BTAI) Research & Development (2022 - 2025)

BioXcel Therapeutics (BTAI) has 4 years of Research & Development data on record, last reported at $8.7 million in Q3 2025.

  • For Q3 2025, Research & Development rose 71.34% year-over-year to $8.7 million; the TTM value through Sep 2025 reached $29.5 million, down 14.56%, while the annual FY2024 figure was $30.4 million, 63.91% down from the prior year.
  • Research & Development reached $8.7 million in Q3 2025 per BTAI's latest filing, down from $10.3 million in the prior quarter.
  • Across five years, Research & Development topped out at $32.7 million in Q4 2022 and bottomed at $4.6 million in Q1 2025.
  • Average Research & Development over 4 years is $15.3 million, with a median of $11.4 million recorded in 2024.
  • Peak YoY movement for Research & Development: crashed 74.0% in 2024, then surged 71.34% in 2025.
  • A 4-year view of Research & Development shows it stood at $32.7 million in 2022, then crashed by 69.63% to $9.9 million in 2023, then plummeted by 40.6% to $5.9 million in 2024, then soared by 48.11% to $8.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $8.7 million in Q3 2025, $10.3 million in Q2 2025, and $4.6 million in Q1 2025.